BIND Therapeutics


UPDATE: Cowen Reiterates Outperform On BIND Therapeutics Following Clinical Updates

Cowen’s healthcare analyst Eric Schmidt is weighing in with some thoughts on BIND Therapeutics (NASDAQ:BIND), as the company yesterday announced an upbeat strategic overview for 2015, along with …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts